Low-Dose Nivolumab Shows Responses in Retrospective Nepal Cancer Cohort
A retrospective Nepalese cohort of 31 patients associated 20- or 40-milligram nivolumab with responses across advanced cancers, but uncontrolled evidence ...
A retrospective Nepalese cohort of 31 patients associated 20- or 40-milligram nivolumab with responses across advanced cancers, but uncontrolled evidence ...
A prospective Phase II trial in Japan found that biweekly gemcitabine plus nab-paclitaxel produced a 47.1 percent response rate and ...
A systematic review of 542 patients finds ruxolitinib-based regimens achieve an 87.2 percent overall response rate in hemophagocytic lymphohistiocytosis, with ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine